JP2012505227A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505227A5
JP2012505227A5 JP2011531146A JP2011531146A JP2012505227A5 JP 2012505227 A5 JP2012505227 A5 JP 2012505227A5 JP 2011531146 A JP2011531146 A JP 2011531146A JP 2011531146 A JP2011531146 A JP 2011531146A JP 2012505227 A5 JP2012505227 A5 JP 2012505227A5
Authority
JP
Japan
Prior art keywords
antibody
agent
antagonist
osteoporosis
produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011531146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505227A (ja
JP5860699B2 (ja
Filing date
Publication date
Priority claimed from US12/246,715 external-priority patent/US7837994B2/en
Application filed filed Critical
Priority claimed from PCT/US2009/059865 external-priority patent/WO2010042634A1/en
Publication of JP2012505227A publication Critical patent/JP2012505227A/ja
Publication of JP2012505227A5 publication Critical patent/JP2012505227A5/ja
Application granted granted Critical
Publication of JP5860699B2 publication Critical patent/JP5860699B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011531146A 2008-10-07 2009-10-07 骨粗鬆症の治療のためのil−20アンタゴニストの使用 Expired - Fee Related JP5860699B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/246,715 US7837994B2 (en) 2008-10-07 2008-10-07 Use of anti-IL-20 antibody for treating osteoporosis
US12/246,715 2008-10-07
US23866109P 2009-08-31 2009-08-31
US61/238,661 2009-08-31
PCT/US2009/059865 WO2010042634A1 (en) 2008-10-07 2009-10-07 Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015214727A Division JP2016041730A (ja) 2008-10-07 2015-10-30 リウマチ性関節炎の治療のためのil−20アンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2012505227A JP2012505227A (ja) 2012-03-01
JP2012505227A5 true JP2012505227A5 (enExample) 2012-11-22
JP5860699B2 JP5860699B2 (ja) 2016-02-16

Family

ID=42100943

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011531146A Expired - Fee Related JP5860699B2 (ja) 2008-10-07 2009-10-07 骨粗鬆症の治療のためのil−20アンタゴニストの使用
JP2015214727A Pending JP2016041730A (ja) 2008-10-07 2015-10-30 リウマチ性関節炎の治療のためのil−20アンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015214727A Pending JP2016041730A (ja) 2008-10-07 2015-10-30 リウマチ性関節炎の治療のためのil−20アンタゴニストの使用

Country Status (7)

Country Link
EP (1) EP2340039B1 (enExample)
JP (2) JP5860699B2 (enExample)
KR (1) KR101691534B1 (enExample)
CN (1) CN102281898B (enExample)
CA (1) CA2739794A1 (enExample)
DK (1) DK2340039T3 (enExample)
WO (1) WO2010042634A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011239520A1 (en) * 2010-04-16 2012-11-08 National Cheng Kung University Treating disorders associated with IL-20 receptor-mediated signaling pathway by blocking IL-20 receptor activity
WO2014006230A1 (en) 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
CA2878825A1 (en) * 2012-07-10 2014-01-16 The Uab Research Foundation Compositions and methods for modulation of il-20 family cytokine activity
US8603470B1 (en) * 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9376490B2 (en) * 2014-04-01 2016-06-28 National Cheng Kung University Treatment of inflammatory pain using IL-20 antagonists
CN107249630A (zh) * 2014-11-24 2017-10-13 国家健康与医学研究院 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
US9982043B2 (en) 2016-06-03 2018-05-29 National Cheng Kung University Use of IL-20 antagonists for treating pancreatic cancer
KR101796025B1 (ko) 2017-04-25 2017-11-10 가톨릭대학교 산학협력단 사포그릴레이트, 프라바스타틴 및 tnf-억제제를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학조성물
CN121800920B (zh) * 2026-03-06 2026-07-31 遵义北科融汇生命科技有限公司 脐带间充质干细胞与外周血prp联合在治疗膝关节炎中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6649779B2 (en) * 1997-05-02 2003-11-18 Wyeth Estrenes
ES2218872T3 (es) * 1997-11-26 2004-11-16 Zymogenetics Inc Polipeptido 10 de tipo citoquina de mamifero.
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
RU2279441C2 (ru) * 1999-12-23 2006-07-10 Займодженетикс, Инк. Выделенный растворимый il-20 рецептор (варианты)
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
ES2387394T3 (es) * 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP1429779A2 (en) * 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
CA2465499A1 (en) * 2001-11-08 2003-05-15 Merck & Co., Inc. Compositions and methods for treating osteoporosis
US7435800B2 (en) * 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
EP1697418A2 (en) * 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2007116818A1 (ja) * 2006-03-30 2007-10-18 Toray Industries, Inc. 樹状ポリエステル、その製造方法および熱可塑性樹脂組成物
JP5330829B2 (ja) * 2006-08-04 2013-10-30 憲弘 西本 関節リウマチ患者の治療予後予測方法

Similar Documents

Publication Publication Date Title
US11639388B2 (en) CD3 antigen binding fragment and application thereof
US8426562B2 (en) Methods and compositions for modulating tumor cell activity
JP2018506961A5 (enExample)
JP2017149720A5 (enExample)
JP2009529920A5 (enExample)
JP2020504076A5 (enExample)
JP2017535257A5 (enExample)
JP2018519364A5 (enExample)
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2022514179A5 (enExample)
JP2023549537A5 (enExample)
JP2012012402A5 (enExample)
JP2025500971A5 (enExample)
JP2012525854A5 (enExample)
US20240117035A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP2013519367A5 (enExample)
JP2019512523A5 (enExample)
JP2007526908A5 (enExample)
JP2021520201A5 (enExample)
JP2022512905A5 (enExample)
KR20210138674A (ko) Tsg-6 항체 및 그 용도
TW202300527A (zh) 使用grem1拮抗劑治療疾病的方法
WO2019172165A1 (ja) 異所性骨化の治療又は予防のための医薬組成物
CN120712286A (zh) 抗体、抗原结合片段和使用方法
CN114729036A (zh) 抗干细胞因子抗体及其使用方法